Advances in medical diagnostics and personalized therapy require robust, sensitive yet cost-effective diagnostic tools for rapid measurement of biomolecules including proteins in body fluids. State-of-the-art technologies are complex and rely on expensive or custom made detection system, and therefore, cannot be readily adapted for point-of-care (POC) analysis. The development of a novel detection platform, which leverages horseradish peroxidase (HRP)-mediated silver precipitation within antibody immobilized porosity tuned poly (ethylene) glycol diacrylate (PEGDA) hydrogel microparticles with the operational advantages of suspension arrays for sensitive quantification of biomarkers, is described. In this study, vascular endothelial growth factor (VEGF) has been used as a model protein. The silver deposition corresponded to the concentration of VEGF in solution. The detection limit of 5.2 ± 1.0 pg/mL and assay time of 2 h highlights that this assay exceeds the conventional technologies in terms of sensitivity and speed. The practical applicability of the hydrogel microparticle based detection system has been established by demonstrating the ability of the system to quantify the production of VEGF by highly aggressive (MDA-MB-231) and non-aggressive (MCF-7) breast cancer cells. The reliance on simple instrument for quantification of clinically relevant markers bolsters the adaptability of the detection platform/method in POC settings.

中文翻译：

---

基于水凝胶的悬浮阵列用于使用辣根过氧化物酶介导的银沉淀进行生物标志物检测

医学诊断和个性化治疗的进步需要强大、灵敏且具有成本效益的诊断工具，以快速测量包括体液中蛋白质在内的生物分子。最先进的技术很复杂，并且依赖于昂贵的或定制的检测系统，因此不能很容易地适用于即时 (POC) 分析。描述了一种新型检测平台的开发，该平台利用辣根过氧化物酶 (HRP) 介导的抗体固定孔隙度调节聚（乙二醇）二丙烯酸酯 (PEGDA) 水凝胶微粒内的银沉淀，并具有悬浮阵列的操作优势，可对生物标志物进行灵敏定量。 . 在这项研究中，血管内皮生长因子 (VEGF) 已被用作模型蛋白。银沉积对应于溶液中VEGF的浓度。5.2 ± 1.0 pg/mL 的检测限和 2 小时的测定时间突出表明该测定在灵敏度和速度方面超过了传统技术。基于水凝胶微粒的检测系统的实际适用性已通过证明该系统量化高侵袭性 (MDA-MB-231) 和非侵袭性 (MCF-7) 乳腺癌细胞产生 VEGF 的能力而建立。对临床相关标志物量化的简单仪器的依赖增强了检测平台/方法在 POC 设置中的适应性。基于水凝胶微粒的检测系统的实际适用性已通过证明该系统量化高侵袭性 (MDA-MB-231) 和非侵袭性 (MCF-7) 乳腺癌细胞产生 VEGF 的能力而建立。对临床相关标志物量化的简单仪器的依赖增强了检测平台/方法在 POC 设置中的适应性。基于水凝胶微粒的检测系统的实际适用性已通过证明该系统量化高侵袭性 (MDA-MB-231) 和非侵袭性 (MCF-7) 乳腺癌细胞产生 VEGF 的能力而建立。对临床相关标志物量化的简单仪器的依赖增强了检测平台/方法在 POC 设置中的适应性。